RSS Feed for Latest Medical Headlines on RxPG News

Medical Research Health Special Topics World

 Asian Health
 Food & Nutrition
 Men's Health
 Mental Health
 Occupational Health
 Public Health
 Sleep Hygiene
 Women's Health
 Canada Healthcare
 China Healthcare
 India Healthcare
 New Zealand
 South Africa
 World Healthcare
   Latest Research
 Alternative Medicine
 Clinical Trials
 Infectious Diseases
  Anti Cancer Drugs
  Anti-Clotting Drugs
  Fatty Acids
 Sports Medicine
   Medical News
 Awards & Prizes
   Special Topics
 Odd Medical News

Latest Research : Pharmacology : Anti Cancer Drugs
  Last Updated: Nov 2, 2013 - 11:52:55 AM

Latest Research : Pharmacology : Anti Cancer Drugs
Anti-angiogenics: a novel class of drugs against solid tumors
Researchers at the University of Minnesota have developed novel anti-cancer drugs to treat solid tumors. These "small molecules" belong to a class of pharmaceutical agents called anti-angiogenics. The new compounds are a refined form of drugs that effectively reduce blood flow to the tumor, thereby inhibiting tumor growth.
Jul 6, 2006 - 3:04:00 AM

Latest Research : Pharmacology : Anti Cancer Drugs : Rituximab
Rituximab effective in treating chronic graft-versus-host disease
A study by Dana-Farber Cancer Institute researchers offers the strongest evidence yet of the effectiveness of a novel therapy for chronic graft-versus-host disease (GVHD), a potentially life-threatening complication of donor bone marrow and stem cell transplants.
Mar 24, 2006 - 7:15:00 PM

Latest Research : Pharmacology : Anti Cancer Drugs : Tarvacin
Tarvacin(TM) Anti-Viral Hepatitis C Clinical Program in Acceleration Phase
Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a biopharmaceutical company with a portfolio of innovative, clinical-stage product candidates for viral diseases and cancer, today announced that it has accelerated its clinical program for Tarvacin(TM) Anti-Viral for the treatment of chronic hepatitis C virus infection (HCV).
Jan 18, 2006 - 6:01:00 PM

Latest Research : Pharmacology : Anti Cancer Drugs : Tarvacin
Tarvacin effective in controlling Pancreatic Cancer
Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a biopharmaceutical company with a portfolio of innovative, clinical-stage product candidates for viral diseases and cancer, today announced preclinical results showing that 3G4, the mouse equivalent of Tarvacin(TM) Anti-Cancer, was effective at controlling the growth and spread of pancreatic cancer as a single agent and had significantly enhanced efficacy when combined with the standard-of-care chemotherapy gemcitabine.
Jan 11, 2006 - 7:21:00 PM

Latest Research : Pharmacology : Anti Cancer Drugs : Rituximab
Rituximab maintenance therapy dramatically improves survival in lymphoma
Two years of maintenance therapy with MabThera (rituximab) dramatically improves the chances of survival for patients suffering from one of the most frequent forms of lymphoma, indolent non-Hodgkin’s Lymphoma (NHL). The trial showed that the risk of death is halved for patients who receive MabThera maintenance therapy, compared to those who receive no maintenance treatment, irrespective of their initial therapy. “We are conscious that these results open a new era in the management of indolent NHL“, said William M. Burns, CEO of the Pharmaceuticals Division at Roche. “Maintenance therapy with MabThera showed unprecedented survival benefits in a serious cancer disease which is currently considered incurable.”
Dec 13, 2005 - 3:36:00 PM

Latest Research : Pharmacology : Anti Cancer Drugs : Tarvacin
Peregrine Pharmaceuticals Evaluating Therapeutic Opportunities for Tarvacin

Oct 25, 2005 - 5:11:00 AM

Latest Research : Pharmacology : Anti Cancer Drugs
Balancing Chk1 activity might produce less toxic cancer drugs
A study published by The Burnham Institute in the September edition of Molecular Cell reports that a cell-cycle checkpoint protein, known to be activated by an important class of anticancer drugs, may play crucial roles in both the hampering of therapeutic actions and aiding cancer cells to "recover" and start dividing again after treatment with these drugs. The study is expected to help academic researchers and biotechnology and pharmaceutical companies design drugs that combat cancer using this checkpoint protein, but with fewer side effects.
Sep 4, 2005 - 8:33:00 AM

Latest Research : Pharmacology : Anti Cancer Drugs : Rituximab
Rituximab to be Considered for Front-Line Treatment of Intermediate Grade or Aggressive CD-20-positive, B-cell, non-Hodgkin's lymphoma
Genentech, Inc. , Biogen Idec, Inc. and Roche (SWX Zurich) today announced that the companies completed the filing of a supplemental Biologics License Application (sBLA) with the U.S. Food and Drug Administration (FDA) for an additional indication for Rituxan(R) (Rituximab), in previously untreated (front-line) patients with intermediate grade or aggressive, CD-20-positive, B-cell, non-Hodgkin's lymphoma (NHL) in combination with CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) or other anthracycline-based chemotherapy regimens.
Aug 18, 2005 - 11:45:00 AM

Latest Research : Pharmacology : Anti Cancer Drugs : Tarvacin
Tarvacin(TM) starts with Phase I study against Hepatitis C Virus
Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), announced today the initiation of a phase I anti-viral study of Tarvacin(TM), the Company's first Anti-Phospholipid Therapy candidate. The phase I study is an open-label, dose-escalation study in up to 32 adult patients with chronic hepatitis C virus (HCV) infection who either no longer respond to or failed standard therapy with pegylated interferon and ribavirin combination therapy.
Aug 8, 2005 - 5:40:00 PM

Latest Research : Pharmacology : Anti Cancer Drugs : Tarvacin
New data support broad anti-viral potential of Tarvacin(TM)
The data presented at BIO 2005 showed that Tarvacin(TM) binds to enveloped virus particles representing 6 different virus families, binds to virally infected cells and inhibits viral replication in multiple virus systems. The data also indicated that Tarvacin(TM) provided significant protection against Cytomegalovirus (CMV) and Pichinde virus (an in vivo Lassa fever model) infections.
Aug 1, 2005 - 12:00:00 AM

Latest Research : Pharmacology : Anti Cancer Drugs : Tarvacin
Tarvacin(TM) also useful in imaging solid tumors
Peregrine Pharmaceuticals, Inc reported that data was presented at the American Association for Cancer Research (AACR) Annual Meeting in Anaheim, California showing the potential use of Tarvacin(TM), its lead Anti-Phospholipid Therapy agent, for imaging solid tumors.
Jul 31, 2005 - 11:13:00 PM

Latest Research : Pharmacology : Anti Cancer Drugs : Tarvacin
Tarvacin(TM) to be evaluated for the treatment of Lassa fever
Peregrine Pharmaceuticals Inc. has announced that it has signed a Cooperative Research and Development Agreement (CRADA) for Material Transfer with the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) to evaluate the potential therapeutic application of Tarvacin(TM) to treat hemorrhagic diseases resulting from Ebola and Marburg viral infections.
Jul 31, 2005 - 11:02:00 PM

Latest Research : Pharmacology : Anti Cancer Drugs : Rituximab
Rituximab may also benefit people with lupus
A drug used to treat cancer may also benefit people with lupus who have complications of the central nervous system. Rheumatologists at the Annual European Congress of Rheumatology in Vienna, Austria heard today (Thursday 9 June) that rituximab is the first drug in a quarter of a century that is making a real impact, and an alternative to previous standard treatments of high-dose steroids, and chemotherapy.
Jun 9, 2005 - 1:26:00 PM

Latest Research : Pharmacology : Anti Cancer Drugs : Rituximab
DANCER Study shows RA drug rituximab is safe and well-tolerated
In the biggest study of its kind, researchers have shown that the drug rituximab, used to treat rheumatoid arthritis (RA) is safe and effective. The results were presented for the first time today (Thursday 9 June), at the Annual European Congress of Rheumatology, EULAR 2005, in Vienna.
Jun 9, 2005 - 1:26:00 PM

Latest Research : Pharmacology : Anti Cancer Drugs
PXD101: A Small Molecule HDAC Inhibitor for Advanced Solid Tumors
CuraGen Corporation (Nasdaq: CRGN - News) and TopoTarget A/S announced that preliminary Phase I data on PXD101, a small molecule histone deacetylase (HDAC) inhibitor, for the treatment of advanced solid tumors were presented today at the American Society of Clinical Oncology (ASCO) Annual Meeting in Orlando, Florida.
May 17, 2005 - 8:43:00 AM

Latest Research : Pharmacology : Anti Cancer Drugs
FDA Permits Phase IIb Kidney Transplant Trial
Isotechnika Inc. announced today that the Company has received permission from the Food and Drug Administration of the United States to proceed with a Phase IIb kidney transplant trial for its lead immunosuppressive drug, ISA247.
May 13, 2005 - 5:45:00 PM

Latest Research : Pharmacology : Anti Cancer Drugs
TNFerade(TM) to be Studied for Locally Advanced Pancreatic Cancer Using Electronic Data Capture Solution
Phase Forward (NASDAQ: PFWD), a leading provider of data management solutions for clinical trials and drug safety, today announced that GenVec, Inc. (NASDAQ: GNVC) has selected Phase Forward's InForm(TM) electronic data capture (EDC) solution to manage a randomized, controlled Phase II clinical trial of its investigational oncology drug, TNFerade(TM).
May 10, 2005 - 8:40:00 PM

Latest Research : Pharmacology : Anti Cancer Drugs
Motexafin Gadolinium Works by Disrupting Key Metabolic Enzymes
The chemotherapy drug motexafin gadolinium (brand name: Xcytrin, manufactured by Pharmacyclics, Inc.) works to thwart cancer cells by disrupting key enzymes involved in cellular metabolism, according to a team of researchers led by Joseph Hacia, Ph.D., assistant professor of biochemistry and molecular biology at the Keck School of Medicine of the University of Southern California.
May 1, 2005 - 8:58:00 PM

<< prev next >>

Gathering information about food is not top priority for individuals with high metabolisms
NIH renews funding for University of Maryland vaccine research
DHA-enriched formula in infancy linked to positive cognitive outcomes in childhood
New IOM report lays out plan to determine effectiveness of obesity prevention efforts
Vitamin D supplementation may delay precocious puberty in girls
Study: Pedometer program helps motivate participants to sit less, move more
Fish oil may stall effects of junk food on brain
Intake of low energy dense food better than skipping meals
Inaugural IOF Olof Johnell Science Award presented to Professor Harry Genant
Molecular hub links obesity, heart disease to high blood pressure
Healthcare experts from UK and India meet at the UK Parliament to discuss ways to improve health care in India, UK
Flu pandemic infected one in five
Stigma preventing leprosy-cured from getting jobs
Measles, Mumps make a comeback in US
Melinda Gates calls on Akhilesh Yadav
'Movies, TV impact tobacco users more than newspapers'
Rockland to open three new hospitals in NCR
Spice Global enters healthcare business with hospital in Delhi
Delhi to expedite recruitment of doctors
India adds spice to US life, keeps it healthy
Latest Research  
How do consumers see a product when they hear music?
Drug activates virus against cancer
Bone loss associated with increased production of ROS
Sound preconditioning prevents ototoxic drug-induced hearing loss in mice
Crystal methamphetamine use by street youth increases risk of injecting drugs
Johns Hopkins-led study shows increased life expectancy among family caregivers
Moderate to severe psoriasis linked to chronic kidney disease, say experts
Licensing deal marks coming of age for University of Washington, University of Alabama-Birmingham
Simple blood or urine test to identify blinding disease
Physician job satisfaction driven by quality of patient care
Medical News  
NHRC issues notice to Kerala over infant deaths
Advanced breast cancer detecting machine comes to India
'Dispel myths about vitiligo'
NHRC summons Odisha chief secretary
Woman dies of swine flu in UP
Maharashtra, GE to modernise rural health care
Hypertension: India's silent killer
Need cautious effort to eradicate polio: Experts
Ayurveda experts develop online personalised health regimen
Soon a detailed study on 'diabesity': Doctors
Special Topics  
MPs express anguish at Delhi gang-rape, Shinde assures fast trial
Worrying rise in number of medical students in prostitution over last 10 years
Behold India's unfolding democratic revolution
Chinese woman cuts open her belly to save surgery cost
Improved Sense of Smell Produced Smarter Mammals
Two-year-old world's first to have extra DNA strand
172,155 kidney stones removed from one patient!
'Primodial Soup' theory for origin of life rejected in paper
Human species could have killed Neanderthal man
History, geography also seem to shape our genome

All rights reserved by RxPG
Contact Us